Published in Pharmacol Biochem Behav on June 01, 1998
The analgesic potential of cannabinoids. J Opioid Manag (2010) 1.16
Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br J Pharmacol (1999) 1.15
Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol (2007) 1.00
The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors. Br J Pharmacol (2008) 0.95
Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology (Berl) (2005) 0.93
Central antinociception induced by mu-opioid receptor agonist morphine, but not delta- or kappa-, is mediated by cannabinoid CB1 receptor. Br J Pharmacol (2009) 0.92
Distribution of CB1 cannabinoid receptors and their relationship with mu-opioid receptors in the rat periaqueductal gray. Neuroscience (2012) 0.91
Cannabinoid receptor-mediated antinociception with acetaminophen drug combinations in rats with neuropathic spinal cord injury pain. Neuropharmacology (2009) 0.88
Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration. J Pharmacol Exp Ther (2013) 0.87
Cannabinoid-induced presynaptic inhibition at the primary afferent trigeminal synapse of juvenile rat brainstem slices. J Physiol (2003) 0.87
[Cannabinoids--signal transduction and mode of action]. Schmerz (2005) 0.87
Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception. Neuropharmacology (2008) 0.85
The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain. Clin J Pain (2014) 0.81
The periaqueductal gray contributes to bidirectional enhancement of antinociception between morphine and cannabinoids. Pharmacol Biochem Behav (2012) 0.78
Cross-tolerance to cannabinoids in morphine-tolerant rhesus monkeys. Psychopharmacology (Berl) (2015) 0.78
A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain. J Neurol (2014) 0.77
Metabotropic glutamate and cannabinoid receptor crosstalk in periaqueductal grey pain processing. Curr Neuropharmacol (2006) 0.77
Functional activity of the cannabinoid 1 receptor is not affected by opioid antagonists in the rat brain. Korean J Anesthesiol (2013) 0.77
Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. Neuropsychopharmacology (2017) 0.75
The Medicinal Cannabis Treatment Agreement: Providing Information to Chronic Pain Patients Through a Written Document. Clin J Pain (2015) 0.75
Effects of Centrally Administered Endocannabinoids and Opioids on Orofacial Pain Perception in Rats. Br J Pharmacol (2017) 0.75
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther (1994) 2.55
mu-Opioid receptor down-regulation and cAMP-dependent protein kinase phosphorylation in a mouse model of chronic morphine tolerance. Brain Res Mol Brain Res (1998) 1.08
Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav (1998) 0.99
Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice. J Pharmacol Exp Ther (1994) 0.98
Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther (1999) 0.96
Involvement of calcium and L-type channels in nicotine-induced antinociception. J Pharmacol Exp Ther (1993) 0.90
The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord. J Pharmacol Exp Ther (1996) 0.88
Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide. Brain Res (2000) 0.86
Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception. Eur J Pharmacol (1999) 0.86
Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. J Pharmacol Exp Ther (1997) 0.85
Antinociceptive activity of intrathecal ketorolac is blocked by the kappa-opioid receptor antagonist, nor-binaltorphimine. Eur J Pharmacol (1993) 0.85
Effects of spinal versus supraspinal administration of cyclic nucleotide-dependent protein kinase inhibitors on morphine tolerance in mice. Drug Alcohol Depend (1997) 0.85
Postpartum women in outpatient drug abuse treatment: correlates of retention/completion. J Psychoactive Drugs (1996) 0.85
Further studies on the antinociceptive effects of delta 6-THC-7-oic acid. Agents Actions (1990) 0.84
In vivo pharmacological effects of dihydro-beta-erythroidine, a nicotinic antagonist, in mice. Psychopharmacology (Berl) (1995) 0.83
Comparative pharmacology of nicotine and ABT-418, a new nicotinic agonist. Psychopharmacology (Berl) (1995) 0.82
Changes in opioid and cannabinoid receptor protein following short-term combination treatment with delta(9)-tetrahydrocannabinol and morphine. J Pharmacol Exp Ther (2001) 0.82
Nicotine-induced antinociception in mice: role of G-proteins and adenylate cyclase. Pharmacol Biochem Behav (1994) 0.82
Inhibition of protein phosphatases alters the expression of morphine tolerance in mice. Eur J Pharmacol (1998) 0.80
The role of minoxidil on endogenous opioid peptides in the spinal cord: a putative co-agonist relationship between K-ATP openers and opioids. Eur J Pharmacol (2001) 0.79
Antisense oligodeoxynucleotides to the kappa-1 receptor block the antinociceptive effects of delta 9-THC in the spinal cord. Brain Res (1995) 0.79
Progress toward understanding the cannabinoid receptor and its second messenger systems. Adv Pharmacol (1994) 0.78
The mouse paw withdrawal assay: a method for determining the effect of calcitonin gene-related peptide on cutaneous heat nociceptive latency time. Life Sci (1993) 0.78
ATP-gated K(+) channel openers enhance opioid antinociception: indirect evidence for the release of endogenous opioid peptides. Eur J Pharmacol (1999) 0.78
Evaluation of cAMP involvement in cannabinoid-induced antinociception. Life Sci (1995) 0.78
Characterization and modulation of acute tolerance to nicotine in mice. J Pharmacol Exp Ther (1996) 0.78
A diminution of delta9-tetrahydrocannabinol modulation of dynorphin A-(1-17) in conjunction with tolerance development. Eur J Pharmacol (1999) 0.78
The effects of dynorphin A (1-13) and U50, 488H on free intracellular calcium in guinea pig cerebellar synaptosomes. Life Sci (1991) 0.78
The role of endogenous peptides in the action of opioid analgesics. Ann Emerg Med (1986) 0.77
Differential effects of divalent cations, cation chelators and an ionophore (A23187) on morphine and dibutyryl guanosine 3': 5'-cyclic monophosphate antinociception. J Pharmacol Exp Ther (1980) 0.76
Antisenses to opioid receptors attenuate ATP-gated K(+) channel opener-induced antinociception. Eur J Pharmacol (1999) 0.76
Alterations in L-type calcium channels in the brain and spinal cord of acutely treated and morphine-tolerant mice. Brain Res (1995) 0.75
A method for the determination of activated receptor phosphorylation state following in vivo drug treatment. Brain Res Brain Res Protoc (1999) 0.75
Comparison of [(3)H]Glyburide binding with opiate analgesia, tolerance, and dependence in ICR and Swiss-Webster mice. J Pharmacol Exp Ther (2000) 0.75
The role of endogenous opioids as mediators of the hypothermic effects of intrathecally administered calcium and calcitonin gene-related peptide in mice. J Pharmacol Exp Ther (1993) 0.75
Interaction of morphine with intrathecally administered calcium and calcium antagonists: evidence for supraspinal endogenous opioid mediation of intrathecal calcium-induced antinociception in mice. J Pharmacol Exp Ther (1988) 0.75
Antisense oligodeoxynucleotides to the kappa1 receptor enhance delta9-THC-induced antinociceptive tolerance. Pharmacol Biochem Behav (1998) 0.75
Modulation of free intracellular calcium and cAMP by morphine and cannabinoids, alone and in combination in mouse brain and spinal cord synaptosomes. Pharmacol Biochem Behav (1994) 0.75
Antinociceptive activity of salmon calcitonin injected intraventricularly in mice: modulation of morphine antinociception. J Pharmacol Exp Ther (1986) 0.75
The hypothermic and antinociceptive effects of intrathecal injection of CGRP (8-37) in mice. Life Sci (1994) 0.75
Blockade of the antinociceptive activity of centrally administered ketorolac by nor-binaltorphimine. Eur J Pharmacol (1995) 0.75
A characterization of the antinociception produced by intracerebroventricular injection of 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate in mice. J Pharmacol Exp Ther (1986) 0.75
Antinociceptive and lethal effects of intraventricularly administered barium and strontium: antagonism by atropine sulfate or naloxone hydrochlorine. Life Sci (1983) 0.75